Feasibility study of pollen-shape drug carriers in dry powder inhalation

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1309-1321

  Hassan, Meer Saiful ^a   Lau, Raymond ^a  

^a Nanyang Technological University   (Singapore)

Author keywords

Aerosols; Dry powder inhalation; Pollen shape carriers; Pulmonary delivery

Indexed keywords

BUDESONIDE; DRUG CARRIER; HYDROXYAPATITE; LACTOSE;

AEROSOL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; DRY POWDER; FEASIBILITY STUDY; GEOMETRY; POLLEN; POWDER INHALER; SYNTHESIS; THERMOGRAVIMETRY; X RAY DIFFRACTION;

EID: 76649096973     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21913     Document Type: Article

References (34)

1. Jaeger HM, Nagel SR, Behringer RP. 1996. The physics of granular matter. Phys Today 49:32-38.
2. Hicky AJ. 2004. Pharmaceutical inhalation aerosol technology. 2nd Edition. New York: Marcel Dekker, Inc.
3. Louey M, Van Oort M, Hickey A. 2004. Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques. Pharm Res 21:1200-1206.
4. Visser J. 1989. Van der Waals and other cohesive forces affecting powder fluidization. Powder Technol 58:1-10.
5. Li Q, Rudolph V, Weigl B, Earl A. 2004. Interparticle van der Waals force in powder flowability and compactibility. Int J Pharm 280:77-93.
6. Guchardi R, Frei M, John E, Kaerger JS. 2008. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations. Int J Pharm 348:10-17.
7. Heng PWS, Chan LW, Lim LT. 2000. Quantification of the surface morphologies of lactose carriers and their effect on the in vitro deposition of salbutamol sulphate. Chem Pharm Bull 48:393-398.
8. Podczeck F. 1999. The influence of particle size distribution and surface roughness of carrier particles on the in vitro properties of dry powder inhalations. Aerosol Sci Technol 31:301-321.
9. Zeng X-M, Martin GP, Marriott C, Pritchard J. 2001. Lactose as a carrier in dry powder formulations: The influence of surface characteristics on drug delivery. J Pharm Sci 90:1424-1434.
10. Srichana T, Martin GP, Marriott C. 1998. On the relationship between drug and carrier deposition from dry powder inhalers in vitro. Int J Pharm 167:13-23.
11. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. 1998. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int J Pharm 172:179-188.
12. Iida K, Hayakawa Y, Okamoto H, Danjo K, Leuenberger H. 2001. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier. Chem Pharm Bull 49:1326.
13. Bell JH, Hartley PS, Cox JSG. 1971. Dry powder aerosols I: A new powder inhalation device. J Pharm Sci 60:1559-1564.
14. French DL, Edwards DA, Niven RW. 1996. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci 27:769-783.
15. Steckel H, Müller BW. 1997. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in vitro deposition. Int J Pharm 154:31-37.
16. Islam N, Stewart P, Larson I, Hartley P. 2004. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures. J Pharm Sci 93:1030-1038.
17. Zeng XM, Martin GP, Marriott C, Pritchard J. 2000. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm 200:93-106.
18. Larhrib H, Martin GP, Marriott C, Prime D. 2003. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm 257:283-296.
19. Larhrib H, Martin GP, Prime D, Marriott C. 2003. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers. Eur J Pharm Sci 19:211-221.
20. Flament M-P, Leterme P, Gayot A. 2004. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers. Int J Pharm 275:201-209.
21. Ganderton D. 1992. The generation of respirable cloud from coarse powder aggregates. J Biopharm Sci 3:101-105.
22. Larhrib H, Cespi M, Dyas MA, Roberts M, Ford JL. 2006. Engineered carrier with a long time of flight (TOF) to improve drug delivery from dry powder inhalation aerosols. Drug Delivery to the Lung (DDL) 17:304-307.
23. Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB. 2002. Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 19:239-245.
24. Wang Y, Hassan MS, Gunawan P, Lau R, Wang X, Xu R. 2009. Polyelectrolyte mediated formation of hydroxyapatite microspheres of controlled size and hierarchical structure. Journal of Colloid and Interface Science, DOI:10.1016/j.jcis.2009.07.023.
25. Shi H, Kleinstreuer C, Zhang Z. 2007. Modeling of inertial particle transport and deposition in human nasal cavities with wall roughness. J Aerosol Sci 38:398-419.
26. Louey M, Van Oort M, Hickey A. 2004. Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations. Pharm Res 21:1207-1213.
27. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. 1997. Large porous particles for pulmonary drug delivery. Science 276:1868.
28. Ikegami K, Kawashima Y, Takeuchi H, Yamamoto H, Isshiki N, Momose D-I, Ouchi K. 2002. Improved inhalation behavior of steroid KSR-592 in vitro with Jethaler® by polymorphic transformation to needle-like crystals (β-form). Pharm Res 19:1439-1445.
29. Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, Langer R, Edwards DA. 1999. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 16:1735-1742.
30. Hinds WC. 1982. Aerosol technology: Properties, behavior, and measurement of airborne particles. 2nd Edition. New York: John Wiley & Sons.
31. Edwards DA. 2002. Delivery of biological agents by aerosols. AIChE J 48:2-6.
32. Larhrib H, Zeng XM, Martin GP, Marriott C, Pritchard J. 1999. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. Int J Pharm 191:1-14.
33. Augsburger LL, Hoag SW. 2008. Pharmaceutical Dosage Forms: Tablets: Volume 1: Unit Operations and Mechanical Properties. New York: Informa Healthcare USA, Inc.
34. Hassan MS, Lau R. 2009. Flow behavior and deposition study of pollen shape carrier particles in an idealized inhalation path model. Particuology in press.